Physician profile
Kandan Baban
NPI 1285954941
$2,970.19
in general payments reported to CMS, 2019-2025
22 companies · $246 in 2025
The $246 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $719 · 2020: $410 · 2021: $950 · 2022: $239 · 2023: $257 · 2024: $149 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $652.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $901.35 | 2019-2025 | Acticor 7 Vr-T Dx, Orsiro Mission |
| Pfizer INC. | $707.38 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $308.31 | 2019-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $159.44 | 2019-2024 | |
| Abbott Laboratories | $135.45 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $84.21 | 2021-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $81.69 | 2019-2022 | |
| Amgen INC. | $81.01 | 2022-2025 | Repatha |
| Irhythm Technologies, INC. | $73.56 | 2023-2024 | Zio Xt Patch |
| Astrazeneca Pharmaceuticals LP | $72.87 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.95 | 2021-2025 | Jardiance |
| Arbor Pharmaceuticals, INC. | $44.06 | 2019-2021 | |
| Esperion Therapeutics, INC. | $41.58 | 2021 | |
| Boston Scientific Corporation | $35.00 | 2022-2023 | Watchman Access System |
| Regeneron Healthcare Solutions, INC. | $31.38 | 2019-2025 | Evkeeza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $27.26 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Actelion Pharmaceuticals US, INC. | $24.58 | 2025 | Opsumit |
| Novo Nordisk INC | $23.20 | 2024 | Ozempic, Rybelsus |
| Medtronic, INC. | $23.01 | 2025 | Mycarelink |
| Philips North America LLC | $22.74 | 2023 | |
| Merck Sharp & Dohme LLC | $22.63 | 2022 | |
| Welch Allyn | $17.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kandan Baban listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.